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Abstract
Enzootic bovine leucosis (EBL) has been assessed according to the criteria of the Animal Health Law
(AHL), in particular criteria of Article 7 on disease proﬁle and impacts, Article 5 on the eligibility of EBL
to be listed, Article 9 for the categorisation of EBL according to disease prevention and control rules as
in Annex IV and Article 8 on the list of animal species related to EBL. The assessment has been
performed following a methodology composed of information collection and compilation, expert
judgement on each criterion at individual and, if no consensus was reached before, also at collective
level. The output is composed of the categorical answer, and for the questions where no consensus
was reached, the different supporting views are reported. Details on the methodology used for this
assessment are explained in a separate opinion. According to the assessment performed, it is
inconclusive whether EBL can be considered eligible to be listed for Union intervention as laid down in
Article 5(3) of the AHL because there was no full consensus on the criteria 5 B(i) and 5 B(iii).
Consequently, since it is inconclusive whether EBL can be considered eligible to be listed for Union
intervention as laid down in Article 5(3) of the AHL, then the assessment on compliance of EBL with
the criteria as in Sections 4 and 5 of Annex IV to the AHL, for the application of the disease prevention
and control rules referred to in points (d) and (e) of Article 9(1), and which animal species can be
considered to be listed for EBL according to Article 8(3) of the AHL is also inconclusive.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
The background and Terms of Reference (ToR) as provided by the European Commission for the
present document are reported in Section 1.2 of the scientiﬁc opinion on the ad hoc methodology
followed for the assessment of the disease to be listed and categorised according to the criteria of
Article 5, Annex IV according to Article 9, and 8 within the Animal Health Law (AHL) framework (EFSA
AHAW Panel, 2017).
1.2. Interpretation of the Terms of Reference
The interpretation of the ToR is as in Section 1.2 of the scientiﬁc opinion on the ad hoc
methodology followed for the assessment of the disease to be listed and categorised according to the
criteria of Article 5, Annex IV according to Article 9, and 8 within the AHL framework (EFSA AHAW
Panel, 2017).
The present document reports the results of assessment on enzootic bovine leukosis (EBL)
according to the criteria of the AHL articles as follows:
• Article 7: EBL proﬁle and impacts
• Article 5: eligibility of EBL to be listed
• Article 9: categorisation of EBL according to disease prevention and control rules as in Annex IV
• Article 8: list of animal species related to EBL.
2. Data and methodologies
The methodology applied in this opinion is described in detail in a dedicated document about the
ad hoc method developed for assessing any animal disease for the listing and categorisation of
diseases within the AHL framework (EFSA AHAW Panel, 2017).
3. Assessment
3.1. Assessment according to Article 7 criteria
This section presents the assessment of EBL according to the Article 7 criteria of the AHL and
related parameters (see Table 2 of the opinion on methodology (EFSA AHAW Panel, 2017)), based on
the information contained in the fact-sheet as drafted by the selected disease scientist (see Section 2.1
of the scientiﬁc opinion on the ad hoc methodology) and amended by the AHAW Panel.
3.1.1. Article 7(a) Disease Proﬁle
3.1.1.1. Article 7(a)(i) Animal species concerned by the disease
Susceptible animal species
Parameter 1 – Naturally susceptible wildlife species (or family/orders)
A single report on detection of bovine leukaemia virus (BLV) antibodies in one free-ranging
European bison (Bison bonasus) from Poland has been published (Kita and Anusz, 1991). Otherwise,
under natural conditions, BLV has not been found in any wild ruminants like deer, llama, antelopes.
Other species have been suspected but not conﬁrmed as naturally susceptible species (e.g. capybara,
rhesus monkeys, chimpanzees) (EFSA AHAW Panel, 2015).
Parameter 2 – Naturally susceptible domestic species (or family/orders)
The following species are considered naturally susceptible among domestic species:
• Bos taurus (domestic cattle),
• Bos indicus (zebu),
• Bubalus bubalis (water buffalo) (EFSA AHAW Panel, 2015),
• Bos grunniens (yak) (Ma et al., 2016).
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Spill over to other domesticated ungulates may occur (primarily in BLV high prevalent areas). The
species having been affected are:
• Ovis aries (domestic sheep) (Green et al., 1988; Pannwitz et al., 1988; Kunakov and Abakin,
1993; Nekoei et al., 2015),
• Vicugna pacos (Huacaya alpaca) (Lee et al., 2012).
Parameter 3 – Experimentally susceptible wildlife species (or family/orders)
No experimentally susceptible wildlife species are known.
Parameter 4 – Experimentally susceptible domestic species (or family/orders)
The following species have been subject to successful experimental infection:
• Ovis aries (domestic sheep),
• Capra aegagrus hircus (domestic goat),
• Oryctolagus cuniculus (common rabbit) (EFSA AHAW Panel, 2015).
Reservoir animal species
Parameter 5 – Wild reservoir species (or family/orders)
There are no wild reservoir species.
Parameter 6 – Domestic reservoir species (or family/orders)
The following domestic species are considered natural reservoir of the disease:
• Bos taurus (domestic cattle),
• Other domesticated bovine animals depending on region: Bos indicus (zebu), Bubalus bubalis
(water buffalo),
• Bos grunniens (mutus) (yak).
3.1.1.2. Article 7(a)(ii) The morbidity and mortality rates of the disease in animal
populations
Morbidity
Parameter 1 – Prevalence/Incidence
The EBL-free Member States (MSs) or regions thereof are laid down in the newest version of
Commission Decision 2003/467/EC1. It was recently amended by Commission Implementing Decision
(EU) 2017/8882. Ofﬁcially free MSs are now Belgium, the Czech Republic, Denmark, Germany, Estonia,
Ireland, Spain, Cyprus, Latvia, Lithuania, Luxembourg, the Netherlands, Austria, Poland, Slovenia,
Slovakia, Finland, Sweden, France (except Reunion Island), the United Kingdom, and in addition, some
provinces in Italy, and Portugal.
On the other hand, the results of the surveillance up to 2015 are presented in the annual report
‘Bovine and Swine Diseases – Situation 2015’.3 The overall herd prevalence was 0.12% by serological
test (827,000 bovine herds tested in European Union (EU)), and 0.01% by examination of bulk milk
samples (84,361 bovine herds tested). The between-herd serological prevalence in MSs with
seroprevalence > 0 is reported in Table 1. Prevalence estimates of BLV infection in the USA, Argentina,
Chile, Japan, and select areas of Canada, China and Iran are reported in Table 2.
The between-herd prevalence of BLV in non-European countries are summarised in Table 2.
1 2003/467/EC: Commission Decision of 23 June 2003 establishing the ofﬁcial tuberculosis, brucellosis, and enzootic-bovine-
leukosis-free status of certain Member States and regions of Member States as regards bovine herds. OJ L 156, 25.6.2003,
p. 74–78.
2 Commission Implementing Decision (EU) 2017/888 of 22 May 2017 amending Decision 2003/467/EC as regards the ofﬁcial
tuberculosis-free status of the region of Umbria of Italy and of the enzootic-bovine-leukosis-free status of Poland, amending
Decision 2004/558/EC as regards the infectious bovine rhinotracheitis-free status of Germany, and amending Decision
2008/185/EC as regards the Aujeszky’s disease-free status of certain regions of Poland and the approval of the eradication
programme for Aujeszky’s disease for the region of Veneto of Italy. OJ L 135, 24.5.2017, p. 27–34.
3 https://ec.europa.eu/food/sites/food/ﬁles/animals/docs/la_bovine_final_report_2015.pdf
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Parameter 2 – Case-morbidity rate (% clinically diseased animals out of infected ones)
Infected animals, after a latency that extends from a few months to several years, develop a
polyclonal proliferation of B cells called persistent lymphocytosis in 30–50% of cases. Persistent
lymphocytosis is usually stable for several years but it may also evolve to lymphoma, a malignant
tumour of lymphoid tissue, which is the main clinical manifestation of BLV infection. Animals with
persistent lymphocytosis have a higher probability of developing lymphoma, thus it is considered as a
pre-tumour stage (EFSA AHAW Panel, 2015).
Regarding lymphoma frequency, the development of lymphomas is a late manifestation of BLV
infection, because lymphomas are recorded at the end of the productive life of animals (at slaughter,
at death or euthanasia in the herd). The number of animals developing lymphomas is usually recorded
per year in the population at risk (period prevalence), but more often it is recorded at slaughter during
meat inspection as the prevalence of animals condemned due to lymphoma. The difﬁculty in assessing
the lymphoma impact over time is that seldom both lymphoma incidence and prevalence of BLV
infection are known (EFSA AHAW Panel, 2015). In Europe before and in the early phases of
eradication period, prevalence of 1% in dairy cows have been recorded for example in Germany,
corresponding to 2–5% of adult cows developing disease. Similarly in Sweden, lymphomas were
diagnosed in approximately 1% of slaughtered cows during the early 1960s from high-prevalence
regions. In more recent times, in the USA the period prevalence in slaughtered cows 2005–2007 was
Table 1: Seroprevalence of BLV infection in infected MSs in 2015
Member state
% infected herds
against tested
Number of bovine
herds tested
Total no.
of herds
Bulgaria 12.95% 1,228 71,850
Greece 1.09% 2,580 38,951
Croatia 0.30% 17,647 32,753
Hungary 0.52% 7,533 16,243
Italy 0.01% 26,175 75,457
Lithuania 0.18% 14,008 64,771
Latvia 0.03% 6,803 26,286
Malta 2.47% 162 182
Poland 0.05% 74,186 526,033*
Portugal 0.02% 5,828 33,426
Romania 0.11% 599,754 600,937
*: Empty herds and herds with animals under 24 months of age – 43,426; The ﬁgures include also not ofﬁcially free regions
(zachodniopomorskie voivodship: bialogardzki, choszczenski, drawski, goleniowski, kolobrzeski, lobeski, pyrzycki, stargardzki,
walecki regions): with 2,492 herds in which 2 infected herds were detected, and 99,91% free herds.
Source: European Commission (2015).
Table 2: Prevalence of BLV infection in the USA, Argentina, Chile, Japan and select areas of
Canada, China and Iran
Country (year) Animal prevalence Herd prevalence Reference
Canada (2002)
province Manitoba
province Alberta
60.8% (dairy cattle)
10.3% (beef cattle)
26.9% (dairy cattle)
97.4% (dairy cattle)
47.9% (beef cattle)
86.7% (dairy cattle)
VanLeeuwen et al., (2006)
Scott et al., (2006)
USA (2007) 83.9% (dairy cattle) APHIS (2008)
Argentina (2001) 32.9% (dairy cattle) 84% (dairy cattle) Trono et al. (2001)
Chile (2009) 59% (dairy cattle) Felmer et al. (2009)
Japan (2011) 35.2% (dairy and beef
cattle)
78% (dairy cattle)
69% (beef cattle)
Murakami et al. (2013)
China
North-East (2014)
6 provinces
15 provinces
18.3% (dairy and beef
cattle)
49.1% (dairy cattle)
1.6% (beef cattle)
21.24% (dairy and
beef cattle)
Sun et al. (2015)
Yang et al. (2016)
Iran Isfahan Province 81.9% (dairy cattle) Morovati et al. (2012)
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0.8%, while in Canada prevalence in slaughter cattle in high BLV-prevalence region in the period
1999–2012 was 0.5% (EFSA AHAW Panel, 2015).
Due to the uncertainty in estimating the frequency of lymphomas due to BLV infection, in countries
with modern dairy production systems and no control programme for EBL, the best estimate of the
cumulative lymphoma incidence in BLV-infected cows is 1–2%, mostly in cattle older than 3–5 years.
In high prevalence herds, the cumulative lymphoma incidence among dairy cows may reach 5%.
The morbidity and mortality due to EBL in the EU is currently negligible as a consequence of strict
control measures applied since the 1990s. Since 2011, only 19 conﬁrmed lymphoma cases have been
reported from all MSs (European Commission, 2011a, 2012, 2013, 2014, 2015).
Mortality
Parameter 3 – Case-fatality rate
The malignant tumoral form of BLV infection (lymphomas) invariably lead to death of the animal
within months, thus with a case-fatality rate of 100% (EFSA AHAW Panel, 2015).
3.1.1.3. Article 7(a)(iii) The zoonotic character of the disease
Presence
Parameter 1 – Report of zoonotic human cases (anywhere)
BLV genome sequences have been found in breast cancer tissue, but no evidence has indicated an
aetiological role of BLV in human disease (Buehring et al., 2001, 2014, 2015; Baltzell et al., 2009).
3.1.1.4. Article 7(a)(iv) The resistance to treatments, including antimicrobial resistance
Parameter 1 – Resistant strain to any treatment even at laboratory level
No treatment is applied, thus no resistance to treatment is reported.
3.1.1.5. The persistence of the disease in an animal population or the environment
Animal population
Parameter 1 – Duration of infectious period in animals
Following infection animals carry virus for the remainder of their life in lymphocytes and are
potentially infectious lifelong. Animals with high viral load are shown to be more infectious compared
to low viral load animals (EFSA AHAW Panel, 2015).
Parameter 2 – Presence and duration of latent infection period
A few weeks after infection, the viral load in blood reaches the level turning the animal potentially
infectious (EFSA AHAW Panel, 2015).
Parameter 3 – Presence and duration of the pathogen in healthy carriers
The majority of infected animals do not show any signs of the disease or the signs are very mild
and unspeciﬁc, while 5–10% of BLV-infected animals can develop lymphoma 3–5 years after infection
(EFSA AHAW Panel, 2015).
Environment
Parameter 4 – Length of survival (dpi) of the agent and/or detection of DNA in selected matrices (soil,
water, air) from the environment (scenarios: high and low T)
BLV is associated to cells and viral particles are not excreted in free forms in the environment.
Infected cells may survive for a limited time in blood or milk, they are sensitive to freezing and high
temperatures and are readily inactivated by UV light, thereby losing the ability to replicate and
transmit BLV. BLV-infected cultured cells heated to 60°C or higher for 1 min did not infect inoculated
cells. In vitro at 4°C the BLV in cells survived in blood containing anticoagulant and BLV antibodies for
at least 2 weeks. In blood without BLV antibodies, the virus survived at least for 4 weeks (EFSA AHAW
Panel, 2015).
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3.1.1.6. Article 7(a)(vi) The routes and speed of transmission of the disease between
animals, and, when relevant, between animals and humans
Routes of transmission
Parameter 1 – Types of routes of transmission from animal to animal (horizontal, vertical)
Horizontal: Any mechanism able to transmit blood or infected lymphocytes between animals
should be considered.
• Direct
Contact with body excretions containing BLV-infected lymphocytes (e.g. saliva, milk) may result in
infection of susceptible animals.
The risk of transmission of BLV via semen or embryos has been considered negligible, whereas
natural mating with infected bulls may lead to transmission due to intense direct contact on mating.
• Indirect
Iatrogenic transmission via use of blood-contaminated needles, instruments for tattooing or
dehorning, contaminated gloves for rectal palpation is possible. The use of milking machines compared
to manual milking has also been associated with BLV infection (EFSA AHAW Panel, 2015).
Haematophagus insects (ﬂies) may contribute to the spread of BLV within a herd by mechanically
transferring lymphocytes via biting. Horse ﬂies (Tabanus spp.) may have greater potential to transmit
BLV within herds.
Vertical: Transplacental transmission and/or peri-partum infection may account for 10–25% of
infections (EFSA AHAW Panel, 2015)
Parameter 2 – Types of routes of transmission between animals and humans (direct, indirect, including
food-borne)
This route is not known, although alimentary route has been suggested with unpasteurised bovine
milk containing BLV-infected cells (EFSA AHAW Panel, 2015).
Speed of transmission
Parameter 3 – Incidence between animals and, when relevant, between animals and humans
The rate of transmission between animals is dependent on the within herd prevalence in speciﬁc
herds. Herd management factors (like housing system, calving management) may impact the spread
of the virus within herd (Table 3).
The incidence rate (determined by seroconversion and/or detection of provirus) varies in different
age groups. Perinatal transmission to newborn calves is observed in a minority of births (3–11.5%)
from infected dams. The incidence increases around ﬁrst lactation (EFSA AHAW Panel, 2015).
Table 3: Occurrence of BLV infection within a longitudinal study of a number of dairy herds (USA
and Italy) and the dairy population (Australia and Estonia) for various years between 1972
and 1992
Population Prevalence* Annual incidence* Reference
USA, dairy herd longitudinal study
(1972–1982)
20–34%
12–18%
9.5–18.3%
2.1–5.5%
Kaja et al. (1984)
Australia, dairy herd 42% 24% Dimmock et al. (1991)
Italy, 9 dairy herds longitudinal study
(1976–1980)
11.0–11.7% 3.9% Rutili et al. (1982)
Estonia, dairy cattle national population
(1989–1992)
31.4%
27.2%
14.0%
3.3%
20.7%
12.8%
4.9%
2.8%
Viltrop and Laht (1996)
*: At animal level.
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Parameter 4 – Transmission rate (beta) (from R0 and infectious period) between animals and, when
relevant, between animals and humans
Signiﬁcant differences in transmission parameters have been reported as shown in Table 4.
3.1.1.7. Article 7(a)(vii) The absence or presence and distribution of the disease in the
Union, and, where the disease is not present in the Union, the risk of its
introduction into the Union
Presence and distribution
Parameter 1 – Map where the disease is present in EU
The EBL-free MSs and regions are laid in the newest version of Commission Decision 2003/467/EC
amended by Commission Implementing Decision (EU) 2017/888, and they are listed in Section 3.1.1.2.
Figure 1 shows the seroprevalence up to 2015 presented in the annual report ‘Bovine and Swine
Diseases – Situation 20153’.
Parameter 2 – Type of epidemiological occurrence (sporadic, epidemic, endemic) at MS level
In countries where EBL is still present, the epidemiological occurrence can be considered endemic.
Risk of introduction
Risk of introduction is estimated at EU level. As BLV is present in the EU, this is not assessed here.
Table 4: Transmission rate of BLV infection
Parameter (CI 95%) Population Reference
b = 2.9 (95% CI 1.9–3.7) per year
R0 = 8.9
Dairy cattle, Argentina Monti et al. (2007)
b = 0.62 (0.37-0.89) in 5 months
~ 1.5/year
Dairy cattle, Japan Tsutsui et al. (2010)
Figure 1: Reported seroprevalence of BLV infection in EU up to 2015
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3.1.1.8. Article 7(a)(viii) The existence of diagnostic and disease control tools
Diagnostic tools
See Section 3.1.4.1.
Control tools
Parameter 2 – Existence of control tools (Table 5)
Table 5: Control tools for EBL (EFSA AHAW Panel, 2015)
Goal/method Tool/components Applicability
Eradication –
elimination of
infected animals
Whole herd slaughter Small herds. Low herd prevalence of the
infection. Support for restocking available
‘Test and slaughter’:
Regular testing and prompt culling of infected
animals
Culling of the offspring of infected animals
Safe management practices implied to avoid
spread of the virus between animals
Low or moderate within herd prevalence
Freedom can be achieved if the rate of
removal of positive animals exceeds the annual
incidence rate of infection
Compensation for culled animals.
‘Test and separate’:
Physically separating the infected cattle from
uninfected
Gradual elimination of infected animals by
increased culling frequency in infected group
regular testing of seronegative group and
prompt separation or elimination of positive
animals
In the ﬁnal stage of the eradication
programme ‘test and slaughter’ strategy is
applied
Safe management practices implied to avoid
spread of the virus between animals
High within herd prevalence. Physical
separation possible
Compensation for culled animals
Control –
reduction of the
rate of effective
contacts
Safe herd management practices:
Milk from BLV-negative cows or milk replacer
to feed calves. Milk from BLV-infected cows
can be used after freezing or heat treatment
Chemical dehorning or cautery
Disposable needles or needles sterilised by
boiling between animals
Cleaning and disinfection of equipment used to
assist calving, ear tattooing, feeding and giving
medication between animals
Separate gloves for rectal exploration
Separate calving paddocks for BLV-infected
and uninfected cattle
Removal of calves from cows within 24 hours
of birth but after intake of colostrum
Fly control programme
All herds
Prevention –
avoiding
introduction
Biosecurity measures:
Introduction of animals from certiﬁed BLV
infection free herds
Avoiding contacts with infected animals (e.g.
common pastures)
Avoiding iatrogenic introduction
All herds
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3.1.2. Article 7(b) The impact of diseases
3.1.2.1. Article 7(b)(i) The impact of the disease on agricultural and aquaculture
production and other parts of the economy
The level of presence of the disease in the Union
Parameter 1 – Number of MSs where the disease is present
The MSs that are not ofﬁcially free from BLV infection are Bulgaria, Greece, Croatia, Hungary, Italy,
France, Lithuania, Latvia, Malta, Portugal and Romania (See Sections 3.1.1.2 and 3.1.1.7).
The loss of production due to the disease
Parameter 2 – Proportion of production losses (%) by epidemic/endemic situation
On EU level, the losses can be considered negligible due to low prevalence. On regional and herd
level the losses may be signiﬁcant.
Tumours: As explained in Section 3.1.1.2, the losses due to EBL lymphoma in the EU is currently
negligible (less than 20 cases since 2011), as a consequence of strict control measures applied since
the 1990s. In countries where no control programme is in place and with modern dairy production
systems, the cumulative lymphoma incidence among dairy cows may reach 5% (EFSA AHAW Panel,
2015).
Milk production: Since the impact of BLV infection on reduction of milk yield is difﬁcult to assess
from observational studies because of the inﬂuence of age, herd size, lactation number and genetic
potential, the selection of study design and methods to consider possible confounders is important.
The results of the systematic review conducted by EFSA in 2015 are summarised in Table 6.
Reproduction: The impact is not known and controversial. An increased calving interval in BLV-
positive cows – up to 2 weeks, but there are studies where signiﬁcant impact of BLV infection was not
identiﬁed (EFSA AHAW Panel, 2015).
Mastitis: The impact on udder health is also controversial, while some studies reported an increased
level of somatic cells in milk in BLV-infected cows, in particular for cows with persistent lymphocytosis,
Goal/method Tool/components Applicability
Surveillance –
maintaining
disease/
infection free
status
At herd level:
Serological surveillance – regular testing of
individual or pooled milk or serum samples for
BLV antibodies
At region or country level:
Surveillance for tumours at post-mortem
inspection of slaughter animals
Serological surveillance – regular testing of
representative sample of herds for BLV
antibodies from bulk milk samples or individual
milk or serum samples
Free herds/territories
Table 6: Reduction of milk yield in dairy cows in high-performing dairy herds
Population Indicator/value Reference
Sweden, national dairy
cattle population
2.5% lower milk production in BLV-infected
herds vs non-infected
Emanuelson et al. (1992)
US, 1,006 dairy herds
in 20 states
218 kg per cow (3%) less milk in herds with
test-positive cows produced compared to
herds with no test-positive cows
Ott et al. (2003)
US, Michigan 11.5 kg per cow per year for each
percentage-point increase in the within-herd
prevalence of BLV-infected cows
Erskine et al. (2012)
10,670 Holstein cows from 364
herds in 8 provinces of Canada
11,000 kg/cow less milk compared to the
test-negative cows over their entire
study lifespan
Nekouei et al. (2016b)
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but other studies did not detect signiﬁcant differences between BLV-positive and -negative animals.
The clinical signiﬁcance of these ﬁndings remains inconclusive (EFSA AHAW Panel, 2015).
Cow longevity: the impact on cow longevity is summarised in Table 7.
3.1.2.2. Article 7(b)(ii) The impact of the disease on human health
The impact on human health is estimated only for zoonotic diseases. There is no scientiﬁc grounds
to classify EBL as a zoonotic disease, thus this aspect is not relevant.
3.1.2.3. Article 7(b)(iii) The impact of the disease on animal welfare
Parameter 1 – Severity of clinical signs at case level and related level and duration of impairment
The development of tumours is accompanied by chronic ill health, progressive loss of body
condition, weakness, anaemia and anorexia, attributable to inﬁltration of tumours into various internal
organs. Tumours are not likely to be detected until they cause conspicuous pathophysiological
manifestations. The animal welfare consequences in terms of duration and severity may vary according
to the location and magnitude of the spread of tumours in organs, e.g. heart, kidneys, lungs, central
nervous system or gastrointestinal system. Overall, animals will suffer when tumours have progressed
beyond early stages. It is also likely that BLV-infected cattle suffer considerably during the last months
of their lives due to immunosuppression. In addition, the EBL has signiﬁcant impact on cow longevity
being a cause of early culling of affected animals. (EFSA AHAW Panel, 2015)
3.1.2.4. Article 7(b)(iv) The impact of the disease on biodiversity and the environment
Biodiversity
Parameter 1 – Endangered wild species affected: listed species as in CITES and/or IUCN list
Registered cases of BLV infection in susceptible wildlife species are rare (EFSA AHAW Panel, 2015).
There are 29 potentially BLV susceptible species of Bovidae family in the list of endangered species of
CITES (2016). There is no evidence of BLV infection in endangered species in wildlife.
Parameter 2 – Mortality in wild species
Due to slow development of the disease, the increased mortality due to the disease occurs in older
age classes. Therefore, the potential of the infection to cause increased mortality in wild populations is
not known, it may be most likely minor.
Environment
Parameter 3 – Capacity of the pathogen to persist in the environment and cause mortality in wildlife
The capacity of the BLV to persist in the environment is very low (see parameter 3,
Section 3.1.1.5). The risk of spreading of the infection to wildlife populations through environmental
contamination can be considered negligible.
Table 7: Impact of BLV infection to cattle longevity
Population Estimate Reference
10,670 Holstein cows from 364
herds in 8 provinces of Canada
The difference in the probability of culling or
death between the BLV positive and negative
cohorts gradually increased, from 13.4% at the
second lactation to 26.2% at the seventh
lactation
Nekouei et al. (2016a)
3,849 Holstein dairy cows in 112
herds in Michigan, US
BLV-positive cows were 23% more likely than
their BLV-negative herd mates to die or be
culled
Bartlett et al. (2013)
~ 4200 dairy cows in 104 Michigan
dairy herds, US
Herds with higher rates of BLV had signiﬁcantly
lower longevity
Erskine et al. (2012)
Sweden, national dairy cattle
population
Signiﬁcantly higher rate of culling in BLV
infected herds v. non infected
Emanuelson et al. (1992)
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3.1.3. Article 7(c) Its potential to generate a crisis situation and its potential use
in bioterrorism
BLV is not listed as pathogen to be used in bioterrorism, and due to the epidemiological
characteristics of the disease, has a negligible potential to generate a crisis.
3.1.4. Article 7(d) Feasibility, availability and effectiveness of the following
disease prevention and control measures
3.1.4.1. Article 7(d)(i) Diagnostic tools and capacities
Availability
Parameter 1 – Ofﬁcially/internationally recognised diagnostic tool, OIE certiﬁed
Internationally recognised diagnostic tools according to OIE are listed in Table 8.
Effectiveness
Parameter 2 – Se and Sp of diagnostic test
Limited information exist on the diagnostic accuracy of available diagnostic tests. Most test
evaluations have compared enzyme-linked immunosorbent assay (ELISA) and agar gel
immunodiffusion test (AGID) and found the former to be equally or more sensitive. Relative to
infection, Klintevall et al. (1991) reported that the ELISA test is capable of detecting herds with within-
herd prevalences of 4–5%.
Table 8: Internationally recognised diagnostic tools for EBL (OIE, 2016a)
Aim Matrix Diagnostic test Test characteristics
Antibody
detection
Serum individual Agar gel immunodiffusion test (AGID) Minimal analytical sensitivity:
reference serum E05 diluted
1:10 in negative serum
should be detected as
positive (Council Directive
64/432/EEC(a))
Serum individual
and pooled
Enzyme-linked immunosorbent assay
(ELISA) Indirect and blocking
More sensitive than AGID
Test sensitivity and speciﬁcity
depend on test system and
matrix
E05 reference serum is used
to deﬁne analytical sensitivity
of a test
Milk individual and
pooled
BLV-proviral DNA
detection
Tumour tissue Nested polymerase chain reaction (PCR) Analytical sensitivity:
5-10 target molecules of
proviral DNA
Peripheral blood
mononuclear cells
Virus isolation Peripheral blood
mononuclear cells
In vitro culture of peripheral blood
mononuclear cells from infected animals.
The p24 and gp51 antigens can be
detected in the supernatant of the
cultures by radio-immunoassay (RIA),
ELISA, immunoblot or AGID.
The presence of the BLV particles can be
demonstrated by electron microscopy and
BLV-proviral DNA by PCR
NA
Typing of
tumours
Tumour tissue Histological examination(1) NA
(a): Council Directive 64/432/EEC of 26 June 1964 on animal health problems affecting intra-Community trade in bovine animals
and swine. OJ 121, 29.7.1964, p. 1977–2012.
(1): Not OIE certiﬁed method for diagnosis of EBL. Histological examination supports the diagnosis of malignant tumours but is
not able to distinguish between sporadic lymphomas and those induced by BLV.
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Feasibility
Parameter 3 – Type of sample matrix to be tested (blood, tissue, etc.)
See Parameter 1.
3.1.4.2. Article 7(d)(ii) Vaccination
There are no vaccines available.
3.1.4.3. Article 7(d)(iii) Medical treatments
There is no medical treatment available.
3.1.4.4. Article 7(d)(iv) Biosecurity measures
Availability
Parameter 1 – Available biosecurity measures
BLV is almost exclusively transmitted between herds by movement of infected live cattle. Iatrogenic
transmission contributes mainly to the spread within herd although between herds transmission cannot
be completely excluded via use of blood-contaminated needles, instruments for tattooing or dehorning
as well as rectal palpation using contaminated gloves.
The biosecurity measures directed to eliminate these routes of transmission are:
• Introduction of animals from certiﬁed BLV infection free herds
• Avoiding contacts with infected animals (e.g. common pastures, during transportation, mating)
• Avoiding iatrogenic introduction:
– Use of disposable needles or needles sterilised by boiling
– Use of cleaned and disinfected equipment to assist calving, for ear tattooing, feeding and
medication etc.
– Use of clean gloves for rectal exploration
– Etc.
(EFSA AHAW Panel, 2015).
Effectiveness
Parameter 2 – Effectiveness of biosecurity measures in preventing the pathogen introduction
Biosecurity measures have proved to be very effective in avoiding introduction of the virus to free
herds (EFSA AHAW Panel, 2015).
Feasibility
Parameter 3 – Feasibility of biosecurity measures
The biosecurity measures applied are part of good farming practice and general hygienic measures,
thus do not involve additional expenditures from farmers or governmental institutions if ofﬁcial BLV
control programme is in place including certiﬁcation of free herds.
3.1.4.5. Article 7(d)(v) Restrictions on the movement of animals and products
Availability
Parameter 1 – Available movement restriction measures
In Council Directive 64/432/EEC are laid down movement requirements all bovine categories
(Article 6(2)). Pursuant to Council Directive 98/46/EC, Annex D, Chapter 1B,4 one of the conditions for
ofﬁcially EBL-free herd to retain its free status is, that (ii) ‘any animals introduced into the herd come
from an ofﬁcially EBL-free herd’.
Thus, the movement restrictions on animals from herds not ofﬁcially free are partial as they can be
moved to other herds of the same health status.
4 Council Directive 98/46/EC of 24 June 1998 amending Annexes A, D (Chapter I) and F to Directive 64/432/EEC on health
problems affecting intra-Community trade in bovine animals and swine. OJ L 198, 15.7.1998, p. 22–39.
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Pursuant to Article 6 Point 3, animals from herds not ofﬁcially EBL free are not allowed to move to
slaughter in another MS.
Effectiveness
Parameter 2 – Effectiveness of restriction of animal movement in preventing the between farm spread
BLV is almost exclusively transmitted between herds by movement of infected live cattle. Movement
restrictions have proved to be an effective tool in preventing the spread between herds (EFSA AHAW
Panel, 2015).
Feasibility
Parameter 3 – Feasibility of restriction of animal movement
The movement restrictions are applied at herd level and these restrictions allow limited movement
of animals within the country to herds of the same health status as well as to slaughter without
restrictions. Thus, the movement restrictions do not cause severe consequences to the normal farm
functioning. The impact of these restrictions to farm economy is related to restricted possibilities to sell
live animals for breeding (EFSA AHAW Panel, 2015).
3.1.4.6. Article 7(d)(vi) Killing of animals
Availability
Parameter 1 – Available methods for killing animal
For the eradication of the disease, the selective slaughter of infected animals (‘test and slaughter’
strategy) is applied. Culled animals undergo normal slaughter at abattoirs.
Effectiveness
Parameter 2 – Effectiveness of killing animals (at farm level or within the farm) for reducing/stopping
spread of the disease
Prompt culling of infected animals from herds has proven to be the most effective disease
eradication measure (EFSA AHAW Panel, 2015).
Feasibility
Parameter 3 – Feasibility of killing animals
Culled animals undergo normal slaughter at abattoirs, thus the process of killing of animals does
not imply any speciﬁc arrangements and doesn’t have any extra economic or animal welfare
consequences.
The possible impact of killing of infected animals on farm economy is related to loss of animals
before the end of their productive life. These losses can be considered minor compared to the positive
effects of the disease freedom status on herd health and welfare as well as farm economy.
3.1.4.7. Article 7(d)(vii) Disposal of carcasses and other relevant animal by-products
Parameter 1 – Available disposal option
Animals undergo normal slaughter at abattoirs and their by-products are disposed according to
general rules and regulations for slaughterhouses.5,6 The disposal of by-products in slaughterhouse
facilities guarantees the destruction of the virus without environmental consequences. If parts of the
carcasses showing signs of the disease are not ﬁt for human consumption, those and the blood of
such animals have to be categorised as animal-by products of Category 2 which often implies higher
disposal costs and certain ABP uses are not allowed (e.g. pet food).
5 Regulation (EC) No 1069/2009 of the European Parliament and of the Council of 21 October 2009 laying down health rules as
regards animal by-products and derived products not intended for human consumption and repealing Regulation (EC)
No 1774/2002 (Animal by-products Regulation). OJ L 300, 14.11.2009, p. 1–33.
6 Commission Regulation (EU) No 142/2011 of 25 February 2011 implementing Regulation (EC) No 1069/2009 of the European
Parliament and of the Council laying down health rules as regards animal by-products and derived products not intended for
human consumption and implementing Council Directive 97/78/EC as regards certain samples and items exempt from
veterinary checks at the border under that Directive Text with EEA relevance OJ L 54, 26.2.2011, p. 1–254.
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3.1.5. Article 7(e) The impact of disease prevention and control measures
3.1.5.1. Article 7(e)(i) The direct and indirect costs for the affected sectors and the
economy as a whole
Parameter 1 – Cost of control (e.g. treatment/vaccine, biosecurity)
The cost of control measures depend on type of measures applied in a farm. Control by improved
biosecurity does not cause signiﬁcant additional expenditures for farmers as biosecurity measures
applied are part of good farming practice and general hygienic measures.
If control measures include testing of animals and regrouping/separating infected animals, then
costs are increasing accordingly.
In US the mean annual cost of a test-and-manage control programme was estimated to be 1,765
dollars per herd. The cost of control varied with herd size (Rhodes et al., 2003).
Parameter 2 – Cost of eradication (culling, compensation)
The main costs of the eradication programmes have been related to regular testing of cattle herds,
and compensation for slaughtered infected animals. Some additional costs may be associated with
regrouping and separation of infected animals in high prevalence herds as well as with improvement of
biosecurity measures.
Between 2007 and 2011, the total cost incurred by the Health Service of Lazio Region (Italy) for
the eradication of EBL was estimated in 6,134,694 EUR, of those about 2.5 million were the cost of
the veterinarians labour, 8,864 for the transport, 23,908 for disposal and compensation for culled
animals (Caminiti et al., 2016).
In 1993–2009, EU co-ﬁnanced eradication programmes in MSs with €40,238,125. The measures
funded contained: serological and milk tests of for cattle and cost incurred for compensation of the
owners for the slaughter of animals (European Commission, 2011b). The ﬁnancial contribution by the
Community was 50% of the costs incurred by a MS. For 2009 the maximum of the costs reimbursed
was €0.5 per laboratory test (ELISA or AGID) and €375 per culled animal (Decision 2008/897/EC7).
The EU contribution for EBL eradication programmes was provided to seven MSs (listed in Table 9)
during the period 2005–2010. The estimated 6-year average annual costs (excluding sampling costs)
were in all MSs less than €15 per herd or €11 or less per 10 cows in a national population, with the
exception of Malta, where more funds were needed for compensations for culled animals due to higher
BLV prevalence compared to the other six countries. In other MSs, the costs are mainly related to
testing of cattle. The average annual expenditures in Malta (€1,019 per herd; €426 per 10 cows)
reﬂect the extent of costs during the ﬁrst phases of eradication, when signiﬁcant proportion of animals
has to be culled.
Table 9: Estimated costs of EBL eradication programmes in 2005–2010 in MSs with EU approved
eradication programmes
Member
State
No of cattle
herds (2010)(1)
No of cows(2)
(2010)(1)
EU
support(3) €
Average total
cost(4)€/year
Total
€/herd
per year
Total
€/10 cows
per year
Estonia 4,620 108,850 74,363 24,788 5,4 2,3
Italy 125,880 2,339,240 2,875,854 958,618 7,6 4,1
Latvia 35,100 184,000 263,519 87,840 2,5 4,8
Lithuania 93,050 370,050 295,346 98,449 1,1 2,7
Malta 290 6,930 887,285 295,762 1019,9 426,8
Poland 514,120 2,645,870 6,032,925 2,010,975 3,9 7,6
Portugal 50,040 720,030 2,370,781 790,260 15,8 11,0
(1): Eurostat.
(2): Dairy and beef breeds.
(3): European Commission (online).
(4): Calculated as two times EU support divided by 6 years.
7 Commission Decision of 28 November 2008 approving annual and multi-annual programmes and the ﬁnancial contribution from
the Community for the eradication, control and monitoring of certain animal diseases and zoonoses presented by the Member
States for 2009 and following years (notiﬁed under document number C(2008) 7415). OJ L 322, 2.12.2008, p. 39–49.
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Parameter 3 – Cost of surveillance and monitoring
In regions free of EBL, continued surveillance is based on a combination of serological testing of
adult animals and identiﬁcation of tumours at slaughter (EFSA AHAW Panel, 2015).
The identiﬁcation of tumours at slaughter is part of regular carcass inspection and the additional
costs are related to laboratory investigation of suspect tumours (histology and PCR).
The monitoring of BLV free dairy herds is based on regular testing of individual or pooled (bulk) milk
samples for BLV antibodies by ELISA test from all or representative sample of herds depending of the
stage of the control programme (eradication or maintaining of the free status) (EFSA AHAW Panel, 2015).
The surveillance costs comprise of labour costs of managers of the programme as well as sample
collectors, the cost of materials used for the blood and milk sampling, transportation costs related to
farm visits and the delivery costs of samples and laboratory costs.
In Switzerland, the unit price per tested sample including labour, materials and general laboratory
charges were estimated to be for a blood serum ELISA at 21.70 CHF and for bulk tank milk ELISA at
25 CHF including analysis of samples for BLV and Bovine Herpes Virus 1 antibodies (Reber et al.,
2012).
Data provided in Table 9 largely reﬂect the costs of surveillance (except for Malta) in EU Member
States as the main expenditures have been related to testing of cattle herds.
Parameter 4 – Trade loss (bans, embargoes, sanctions) by animal product
Pursuant to Council Directive 64/432/EEC, Annex D, Chapter 1B, one of the conditions for ofﬁcially
EBL free herd to retain its free status is, that (ii) ‘any animals introduced into the herd come from an
ofﬁcially enzootic-bovine-leukosis-free herd’.
Thus, the movement restrictions to animals from not ofﬁcially free herds are partial as they can be
moved to other herd of the same health status.
Pursuant to Article 6 Point 3, animals from not ofﬁcially EBL free herds are not allowed to move to
slaughter in another member state.
According to Article 11.8.5 of the Chapter 11.8 of the OIE Terrestrial Animal Health Code, the
imported animals should be free of BLV infection. The disease freedom of the animal has to be
certiﬁed by the veterinary service of the exporting country (OIE, 2016b).
Parameter 5 – Importance of the disease for the affected sector (% loss or € lost compared to
business amount of the sector)
Due to the successful eradication of EBL, the impact of the disease on agricultural production in MS
is currently negligible. This statement is also valid for MS with low prevalence of infection but not yet
ofﬁcially free. However, the losses in affected herds are proportional to the within herd prevalence of
the infection (EFSA AHAW Panel, 2015).
In United States, the estimated loss to the dairy industry in 1993 due to BLV caused milk and fat
yields decline associated with persistent lymphocytosis (PL) only was more than $42 million annually in
the situation where at least 50% of Holstein herds were infected with BLV and within infected herds
70% of animals were assumed to be infected and 20% of the infected animals develop PL (Da et al.,
1993).
The loss of productivity in BLV positive dairy herds in USA resulted in a $285 million loss of
economic surplus for producers and $240 million for consumers making a total of $525 million (Ott
et al., 2003).
On herd level, the estimated mean cost to the producer per lymphoma case was 412 dollars and
the mean annual cost of subclinical infection at a 50% prevalence of infection was 6,406 dollars per
100 milking cows in 2003 (Rhodes et al., 2003).
3.1.5.2. Article 7(e)(ii) The societal acceptance of disease prevention and control
measures
There is no evidence of any societal non-acceptance towards EBL control programme.
The possible zoonotic potential of the BLV has been of some concern and has got some attention
of general public in early years after discovery of the virus and more recently in connection with
reports on discovery of the virus in breast tumours of humans.
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3.1.5.3. Article 7(e)(iii) The welfare of affected subpopulations of kept and wild animals
Parameter 1 – Welfare impact of control measures on domestic animals
Implication of control measures does not cause any signiﬁcant impairment of welfare compared to
common herd management practices. More frequent sampling of animals (2–3 times a year) may
cause some additional stress to animals if blood samples are taken. The level of stress caused is
comparable to vaccination procedures. Infected animals are eliminated from the herd by normal
slaughtering in regular abattoirs (EFSA AHAW Panel, 2015).
3.1.5.4. Article 7(e)(iv) The environment and biodiversity
Environment
Parameter 1 – Use and potential residuals of biocides or medical drugs in environmental compartments
(soil, water, feed, manure)
Negligible – limited disinfection measures implied in farms.
3.2. Assessment according to Article 5 criteria
This section presents the results of the expert judgement on the criteria of Article 5 of the AHL
about enzootic bovine leukosis (Table 10). The expert judgement was based on Individual and
Collective Behavioural Aggregation (ICBA) approach described in detail in the opinion on the
methodology (EFSA AHAW Panel, 2017). Experts have been provided with information of the disease
fact-sheet mapped into Article 5 criteria (see supporting information, Annex A), based on that the
experts indicate their Y/N or ‘na’ judgement on each criterion of Article 5, and the reasoning
supporting their judgement.
The minimum number of judges in the judgement was eight. The expert judgement was conducted
as described in the methodological opinion (EFSA AHAW Panel, 2017). For details on the interpretation
of the questions, see Appendix B of the methodological opinion (EFSA AHAW Panel, 2017).
Table 10: Outcome of the expert judgement on the Article 5 criteria for enzootic bovine leukosis
Criteria to be met by the disease:
According to AHL, a disease shall be included in the list referred to in point (b) of paragraph 1
of Article 5 if it has been assessed in accordance with Article 7 and meets all of the following
criteria
Final
outcome
A(i) The disease is transmissible Y
A(ii) Animal species are either susceptible to the disease or vectors and reservoirs thereof
exist in the Union
Y
A(iii) The disease causes negative effects on animal health or poses a risk to public health due
to its zoonotic character
Y
A(iv) Diagnostic tools are available for the disease Y
A(v) Risk-mitigating measures and, where relevant, surveillance of the disease are effective
and proportionate to the risks posed by the disease in the Union
Y
At least one criterion to be met by the disease:
In addition to the criteria set out above at points A(i)–A(v), the disease needs to fulﬁl at least one of the
following criteria
B(i) The disease causes or could cause signiﬁcant negative effects in the Union on animal
health, or poses or could pose a signiﬁcant risk to public health due to its zoonotic
character
NC
B(ii) The disease agent has developed resistance to treatments and poses a signiﬁcant danger
to public and/or animal health in the Union
na
B(iii) The disease causes or could cause a signiﬁcant negative economic impact affecting
agriculture or aquaculture production in the Union
NC
B(iv) The disease has the potential to generate a crisis or the disease agent could be used for
the purpose of bioterrorism
N
B(v) The disease has or could have a signiﬁcant negative impact on the environment,
including biodiversity, of the Union
N
Colour code: green = consensus (Yes/No), yellow = no consensus (NC), red =not applicable (na), i.e. insufﬁcient evidence or
irrelevant to judge.
AHL assessment on enzootic bovine leukosis (EBL)
www.efsa.europa.eu/efsajournal 18 EFSA Journal 2017;15(8):4956
3.2.1. Non-consensus questions
This section displays the assessment related to each criterion of Article 5 where no consensus was
achieved in form of tables (Tables 11 and 12). The proportion of Y, N or na answers are reported,
followed by the list of different supporting views for each answer.
Reasoning supporting the judgement
Supporting Yes:
• In endemic areas within the EU, seroprevalence ranges from 0.01% to 12% (2015), 0% to
1–2% of BLV-infected animals can develop lymphomas. Furthermore, there is evidence that
BLV-infected herds register a reduction in milk yield.
Supporting No:
• The probability to develop lymphomas over the lifespan of the animals is low.
Reasoning supporting the judgement
Supporting Yes:
• On EU level, the losses can be considered negligible due to low prevalence following decades
of control programmes. On regional and herd level, the losses may be signiﬁcant.
• In herds with test-positive cows compared to herds with no test-positive cows, a reduction in
milk yield of 3% has been observed (218 kg/cow). Over the entire study lifespan, the test-
positive herd produced 11,000 kg/cow less milk compared to the test-negative. In MSs
currently BLV-free and where dairy production is important, such as Denmark or Ireland, these
losses would cause a signiﬁcant negative economic impact.
• EBL has a signiﬁcant impact on milk yield (Table 6) and longevity (Table 7), and can be a
cause of early culling of affected animals (EFSA AHAW Panel, 2015). At present, there may be
limited impact of the disease in the Union due to a long-term eradication programme, but if
disease barriers are removed, the prevalence would be expected to increase and could thus
cause signiﬁcant negative effects in the Union.
Supporting No:
• In endemic situations, 1–2% of BLV-infected cattle develop lymphosarcoma, whereas in herds
with higher infection prevalence, up to 5%. Lymphosarcoma is one of the main causes of
condemnation of adult dairy cows at slaughter. However, lymphoma is rarely seen in animals
younger than 2 years of age and is most common in the 4- to 8-year-old age group.
Therefore, most of the affected animals, especially in the dairy sector, will be slaughtered
before the development of lymphoma or before symptoms are evident. In these animals,
lymphomas are generally found as an incidental post-mortem ﬁnding.
Table 11: Outcome of the expert judgement related to criterion 5 B(i)
Question
Final
outcome
Response
Y (%) N (%) na (%)
B(i) The disease causes or could cause signiﬁcant negative
effects in the Union on animal health, or poses or could
pose a signiﬁcant risk to public health due to its
zoonotic character
NC 62 38 0
NC: non-consensus; number of judges: 8.
Table 12: Outcome of the expert judgement related to criterion 5 B(iii)
Question
Final
outcome
Response
Y (%) N (%) na (%)
B(iii) The disease causes or could cause a signiﬁcant
negative economic impact affecting agriculture or
aquaculture production in the Union
NC 62 38 0
NC: non-consensus; number of judges: 8.
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• Experiences from US and Canada should be extrapolated to Europe with care due to important
differences in farm size and structure. Prevalence is generally low and consequences are
therefore not signiﬁcant.
3.2.2. Outcome of the assessment of EBL according to criteria of Article 5(3) of
the AHL on its eligibility to be listed
As from the legal text of the AHL, a disease is considered eligible to be listed as laid down in Article
5 if it fulﬁls all criteria of the ﬁrst set from A(i) to A(v) and at least one of the second set of criteria
from B(i) to B(v). According to the assessment methodology (EFSA AHAW Panel, 2017), a criterion is
considered fulﬁlled when the outcome is ‘Yes’. According to the results shown in Table 10, EBL
complies with all criteria of the ﬁrst set, but not with at least one criterion of the second set because
the assessment is inconclusive on compliance with criteria 5 B(i) and 5 B(iii). Therefore, it is
inconclusive whether EBL can be considered eligible to be listed for Union intervention as laid down in
Article 5(3) of the AHL.
3.3. Assessment according to Article 9 criteria
This section presents the results of the expert judgement on the criteria of Annex IV referring to
categories as in Article 9 of the AHL about EBL (Tables 13–17). The expert judgement was based on
ICBA approach described in detail in the opinion on the methodology. Experts have been provided with
information of the disease fact-sheet mapped into Article 9 criteria (see supporting information, Annex
A), based on that the experts indicate their Y/N or ‘na’ judgement on each criterion of Article 9, and
the reasoning supporting their judgement. The minimum number of judges in the judgement was
eight. The expert judgement was conducted as described in the methodological opinion (EFSA AHAW
Panel, 2017). For details on the interpretation of the questions, see Appendix B of the methodological
opinion (EFSA AHAW Panel, 2017).
Table 13: Outcome of the expert judgement related to the criteria of Section 1 of Annex IV
(category A of Article 9) for enzootic bovine leukosis (CI: current impact; PI: potential
impact)
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
1 The disease is not present in the territory of the Union OR present only in exceptional
cases (irregular introductions) OR present in only in a very limited part of the territory of
the Union
NC
2.1 The disease is highly transmissible N
2.2 There be possibilities of airborne or waterborne or vector-borne spread Y
2.3 The disease affects multiple species of kept and wild animals OR single species of kept
animals of economic importance
Y
2.4 The disease may result in high morbidity and signiﬁcant mortality rates N
At least one criterion to be met by the disease:
In addition to the criteria set out above at points 1–2.4, the disease needs to fulﬁl at least one of the following
criteria
3 The disease has a zoonotic potential with signiﬁcant consequences on public health,
including epidemic or pandemic potential OR possible signiﬁcant threats to food safety
N
4 The disease has a signiﬁcant impact on the economy of the Union, causing substantial
costs, mainly related to its direct impact on the health and productivity of animals
N
5(a)(CI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(a)(PI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(b) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
NC
5(c)(CI) The disease has a signiﬁcant impact on the environment, due to the direct impact of the
disease OR due to the measures taken to control it
N
5(c)(PI) The disease has a signiﬁcant impact on the environment, due to the direct impact of the
disease OR due to the measures taken to control it
N
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5(d)(CI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the
protection of endangered species or breeds, including the possible disappearance or
long-term damage to those species or breeds
N
5(d)(PI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the
protection of endangered species or breeds, including the possible disappearance or
long-term damage to those species or breeds
N
Colour code: green = consensus (Yes/No), yellow = no consensus (NC).
Table 14: Outcome of the expert judgement related to the criteria of Section 2 of Annex IV
(category B of Article 9) for enzootic bovine leukosis (CI: current impact; PI: potential
impact)
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
1 The disease is present in the whole OR part of the Union territory with an endemic
character AND (at the same time) several Member States or zones of the Union are
free of the disease
NC
2.1 The disease is moderately to highly transmissible N
2.2 There be possibilities of airborne or waterborne or vector-borne spread Y
2.3 The disease affects single or multiple species Y
2.4 The disease may result in high morbidity with in general low mortality N
At least one criterion to be met by the disease:
In addition to the criteria set out above at points 1–2.4, the disease needs to fulﬁl at least one of the following
criteria
3 The disease has a zoonotic potential with signiﬁcant consequences on public health,
including epidemic potential OR possible signiﬁcant threats to food safety
N
4 The disease has a signiﬁcant impact on the economy of the Union, causing substantial
costs, mainly related to its direct impact on the health and productivity of animals
N
5(a)(CI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(a)(PI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(b) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
NC
5(c)(CI) The disease has a signiﬁcant impact on the environment, due to the direct impact of
the disease OR due to the measures taken to control it
N
5(c)(PI) The disease has a signiﬁcant impact on the environment, due to the direct impact of
the disease OR due to the measures taken to control it
N
5(d)(CI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the
protection of endangered species or breeds, including the possible disappearance or
long-term damage to those species or breeds
N
5(d)(PI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the
protection of endangered species or breeds, including the possible disappearance or
long-term damage to those species or breeds
N
Colour code: green = consensus (Yes/No), yellow = no consensus (NC).
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Table 15: Outcome of the expert judgement related to the criteria of Section 3 of Annex IV (category
C of Article 9) for enzootic bovine leukosis (CI: current impact; PI: potential impact)
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
1 The disease is present in the whole OR part of the Union territory with an endemic
character
N
2.1 The disease is moderately to highly transmissible N
2.2 The disease is transmitted mainly by direct or indirect transmission Y
2.3 The disease affects single or multiple species Y
2.4 The disease usually does not result in high morbidity and has negligible or no mortality
AND often the most observed effect of the disease is production loss
Y
At least one criterion to be met by the disease:
In addition to the criteria set out above at points 1–2.4, the disease needs to fulﬁl at least one of the following
criteria
3 The disease has a zoonotic potential with signiﬁcant consequences on public health, or
possible signiﬁcant threats to food safety
N
4 The disease has a signiﬁcant impact on the economy of parts of the Union, mainly
related to its direct impact on certain types of animal production systems
N
5(a)(CI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(a)(PI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(b) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
NC
5(c)(CI) The disease has a signiﬁcant impact on the environment, due to the direct impact of
the disease OR due to the measures taken to control it
N
5(c)(PI) The disease has a signiﬁcant impact on the environment, due to the direct impact of
the disease OR due to the measures taken to control it
N
5(d)(CI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the
protection of endangered species or breeds, including the possible disappearance or
long-term damage to those species or breeds
N
5(d)(PI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the
protection of endangered species or breeds, including the possible disappearance or
long-term damage to those species or breeds
N
Colour code: green = consensus (Yes/No), yellow = no consensus (NC).
Table 16: Outcome of the expert judgement related to the criteria of Section 4 of Annex IV
(category D of Article 9) for enzootic bovine leukosis
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
D The risk posed by the disease in question can be effectively and proportionately mitigated
by measures concerning movements of animals and products in order to prevent or limit its
occurrence and spread
Y
The disease fulﬁls criteria of Sections 1, 2, 3 or 5 of Annex IV of AHL NC
Colour code: green = consensus (Yes/No), yellow = no consensus (NC).
Table 17: Outcome of the expert judgement related to the criteria of Section 5 of Annex IV
(category E of Article 9) for enzootic bovine leukosis
Diseases in category E need to fulﬁl criteria of Sections 1, 2 or 3 of Annex IV of AHL
and/or the following:
Final
outcome
E Surveillance of the disease is necessary for reasons relating to animal health, animal welfare,
human health, the economy, society or the environment
(If a disease fulﬁls the criteria as in Article 5, thus being eligible to be listed, consequently
category E would apply.)
NC
Colour code: yellow = no consensus (NC).
AHL assessment on enzootic bovine leukosis (EBL)
www.efsa.europa.eu/efsajournal 22 EFSA Journal 2017;15(8):4956
3.3.1. Non-consensus questions
This section displays the assessment related to each criterion of Annex IV referring to the
categories of Article 9 of the AHL where no consensus was achieved in form of tables (Tables 18 and
19). The proportion of Y, N or ‘na’ answers are reported, followed by the list of different supporting
views for each answer.
Reasoning supporting the judgement
Supporting Yes for 1 (cat. A):
• The disease is present in a limited part of the EU territory or only in exceptional cases as most
MSs (18–28) (i.e. more than several) are EBL-free including the MSs with an important bovine
population.
Supporting Yes for 1 (cat. B):
• Based on the map distribution of the disease in the EU, EBL is present in a limited part of the
EU (mostly in the Balkans). Therefore, endemic infection is present in a very limited part of the
EU cattle population, whereas several MSs or zones of the Union are free of the disease.
Reasoning supporting the judgement
Supporting Yes:
• The prevalence of the disease can be signiﬁcant, e.g. 60% (herd prevalence) in a Canadian
study from 2002, and the impact as well.
• The animal welfare consequences in terms of duration and severity may vary according to the
location and magnitude of the spread of tumours in organs, e.g. heart, kidneys, lungs, central
nervous system or gastrointestinal system. Overall, animals will suffer when tumours have
progressed beyond an early stage.
• In endemic countries, 1–2% of BLV-infected animals develop lymphomas (EFSA AHAW Panel,
2015) and in high prevalence herds the cumulative lymphoma incidence among dairy cows
may reach 5%. In terms of welfare, these are large numbers of animals.
Supporting No:
• Experiences from the US and Canada should be extrapolated to Europe with care due to
important differences in farm size and structure.
Table 18: Outcome of the expert judgement related to criterion 1 of Article 9
Question
Final
outcome
Response
Y (%) N (%) na (%)
1 (cat. A) The disease is not present in the territory
of the Union OR present only in exceptional
cases (irregular introductions) OR present in
only in a very limited part of the territory
of the Union
NC 13 87 0
1 (cat. B) The disease is present in the whole OR part
of the Union territory with an endemic
character AND (at the same time) several Member
States or zones of the Union are free of the disease
NC 87 13 0
NC: non-consensus; number of judges: 8.
Table 19: Outcome of the expert judgement related to criterion 5(b) of Article 9
Question
Final
outcome
Response
Y (%) N (%) na (%)
5(b) The disease has a signiﬁcant impact on animal welfare, by
causing suffering of large numbers of animals
NC 25 75 0
NC: non-consensus; number of judges: 8.
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• Not a large number of animals are affected by the disease, and only the development of
tumours in the last stages is a source of pain. The case-morbidity is overall negligible, even in
animals that have lived long enough to show tumours.
3.3.2. Outcome of the assessment of criteria in Annex IV for EBL for the purpose
of categorisation as in Article 9 of the AHL
As from the legal text of the AHL, a disease is considered ﬁtting in a certain category (A, B, C, D or
E corresponding to point (a) to point (e) of Article 9(1) of the AHL) if it is eligible to be listed for Union
intervention as laid down in Article 5(3) and fulﬁls all criteria of the ﬁrst set from 1 to 2.4 and at least
one of the second set of criteria from 3 to 5(d) as shown in Tables 13–17. According to the
assessment methodology (EFSA AHAW Panel, 2017), a criterion is considered fulﬁlled when the
outcome is ‘Yes’. With respect to different type of impact where the assessment is divided into current
and potential impact, a criterion will be considered fulﬁlled if at least one of the two outcomes is ‘Y’
and, in case of no ‘Y’, the assessment is inconclusive if at least one outcome is ‘NC’.
A description of the outcome of the assessment of criteria in Annex IV for EBL for the purpose of
categorisation as in Article 9 of the AHL is presented in Table 20.
According to the assessment here performed, EBL complies with the following criteria of the
Sections 1 to 5 of Annex IV of the AHL for the application of the disease prevention and control rules
referred to in points (a) to (e) of Article 9(1):
1) To be assigned to category A, a disease needs to comply with all criteria of the ﬁrst set
(1, 2.1–2.4) and according to the assessment EBL complies with criteria 2.2 and 2.3, but not
with criteria 2.1 and 2.4 and the assessment is inconclusive on compliance with criterion 1.
To be eligible for category A, a disease needs to comply additionally with one of the criteria
of the second set (3, 4, 5a–d) and EBL does not comply with any of the criteria and the
assessment is inconclusive on compliance with criterion 5b.
2) To be assigned to category B, a disease needs to comply with all criteria of the ﬁrst set
(1, 2.1–2.4) and according to the assessment EBL complies with criteria 2.2 and 2.3, but not
with criteria 2.1 and 2.4 and the assessment is inconclusive on compliance with criterion 1.
To be eligible for category B, a disease needs to comply additionally with one of the criteria
of the second set (3, 4, 5a–d) and EBL does not comply with any of the criteria and the
assessment is inconclusive on compliance with criterion 5b.
3) To be assigned to category C, a disease needs to comply with all criteria of the ﬁrst set
(1, 2.1–2.4) and according to the assessment EBL complies with criteria 2.2, 2.3 and 2.4, but
Table 20: Outcome of the assessment of criteria in Annex IV for EBL for the purpose of
categorisation as in Article 9 of the AHL
Category
Article 9 criteria
1° set of criteria 2° set of criteria
1 2.1 2.2 2.3 2.4 3 4 5a 5b 5c 5d
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not with 1 and 2.1. To be eligible for category C, a disease needs to comply additionally with
one of the criteria of the second set (3, 4, 5a–d) and EBL does not comply with any of the
criteria and the assessment is inconclusive on compliance with criterion 5b.
4) To be assigned to category D, a disease needs to comply with criteria of Section 1, 2, 3 or 5
of Annex IV of the AHL, whose assessment performed is inconclusive for EBL, and with the
speciﬁc criterion D of Section 4, with which EBL complies.
5) To be assigned to category E, a disease needs to comply with criteria of Section 1, 2 or 3 of
Annex IV of the AHL and/or the surveillance of the disease is necessary for reasons relating
to animal health, animal welfare, human health, the economy, society or the environment.
The latter is applicable if a disease fulﬁls the criteria as in Article 5 and the assessment here
performed for EBL is inconclusive on compliance with the criteria as in Article 5.
3.4. Assessment of Article 8
This section presents the results of the assessment on the criteria of Article 8(3) of the AHL about
EBL. The Article 8(3) criteria are about animal species to be listed, as it reads below:
‘3. Animal species or groups of animal species shall be added to this list if they are affected or if
they pose a risk for the spread of a speciﬁc listed disease because:
a) they are susceptible for a speciﬁc listed disease or scientiﬁc evidence indicates that such
susceptibility is likely; or
b) they are vector species or reservoirs for that disease, or scientiﬁc evidence indicates that such
role is likely’.
For this reason, the assessment on Article 8 criteria is based on the evidence as extrapolated from
the relevant criteria of Article 7, i.e. the ones related to susceptible and reservoir species or routes of
transmission, which cover also possible role of biological or mechanical vectors.8 According to the
mapping, as presented in Table 5, Section 3.2 of the scientiﬁc opinion on the ad hoc methodology
(EFSA AHAW Panel, 2017), the main animal species to be listed for EBL according to the criteria of
Article 8(3) of the AHL are as displayed in Table 21.
4. Conclusions
TOR 1: for each of those diseases an assessment, following the criteria laid down in Article 7 of
the AHL, on its eligibility of being listed for Union intervention as laid down in Article 5(3) of the AHL;
Table 21: Main animal species to be listed for EBL according to criteria of Article 8 (source: data
reported in Section 3.1.1.1)
Class Order Family Genus/Species
Susceptible Mammalia Artiodactyla Bovidae Bos taurus (domestic cattle), Bos indicus (zebu),
Bubalus bubalis (water buffalo), Bos grunniens
(yak), Ovis aries (domestic sheep), Bison bonasus
(European bison), Capra aegagrus hircus
(domestic goat)
Camelidae Vicugna pacos (alpaca)
Lagomorpha Leporidae Oryctolagus cuniculus (common rabbit)
Reservoir Mammalia Artiodactyla Bovidae Bos taurus (domestic cattle), Bos indicus
(zebu), Bubalus bubalis (water buffalo),
Bos grunniens (domestic yak)
Vectors Insecta Diptera Tabanidae Tabanus spp.*
*: Mechanical vectors.
8 A vector is a living organism that transmits an infectious agent from an infected animal to a human or another animal. Vectors
are frequently arthropods. Biological vectors may carry pathogens that can multiply within their bodies and be delivered to new
hosts, usually by biting. In mechanical vectors the pathogens do not multiply within the vector, which usually remains infected
for shorter time than in biological vectors.
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• According to the assessment here performed, it is inconclusive whether EBL can be considered
eligible to be listed for Union intervention as laid down in Article 5(3) of the AHL. Eligibility of
listing EBL is dependent on a decision on criteria 5 B(i) and 5 B(iii).
TOR 2a: for each of the diseases which was found eligible to be listed for Union intervention, an
assessment of its compliance with each of the criteria in Annex IV to the AHL for the purpose of
categorisation of diseases in accordance with Article 9 of the AHL;
• According to the assessment here performed, since it is inconclusive whether EBL can be
considered eligible to be listed for Union intervention as laid down in Article 5(3) of the AHL,
then also the assessment of its compliance with each of the criteria in Annex IV to the AHL for
the purpose of categorisation of diseases in accordance with Article 9 of the AHL is
inconclusive for the assignment to categories (d) and (e) of Article 9 of the AHL.
TOR 2b: for each of the diseases which was found eligible to be listed for Union intervention, a list of
animal species that should be considered candidates for listing in accordance with Article 8 of the AHL.
• According to the assessment here performed, since it is inconclusive whether EBL can be
considered eligible to be listed for Union intervention as laid down in Article 5(3) of the AHL,
then it is also inconclusive which animal species can be considered to be listed for EBL
according to Article 8(3) of the AHL.
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EBL Enzootic bovine leucosis
ELISA enzyme-linked immunosorbent assay
ICBA Individual and Collective Behavioural Aggregation
IUCN International Union for Conservation of Nature
MS Member State
OIE World Organisation for Animal Health
PCR polymerase chain reaction
PL persistent lymphocytosis
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